AstraZeneca plc (ADR) Heart Drug Shows Positive Results; Uplifting Sales Potential

March 16, 2015 1:02 PM

14 0

AstraZeneca Plc. (ADR) (NYSE:AZN) has finally found success for its anti-clotting drug Brilinta, which has proven to be effective in significantly reducing the risk of death from strokes or heart attacks in patients with prior history of the said conditions. The drug is expected to boost the company’s sales in the long run.

The current treatment option available for patients after one year of a heart attack is aspirin for blood thinning; however, AstraZeneca added Brilinta to aspirin as a dual therapy, which proved to be faster and effective than just the drug itself.

Read more

To category page